Opus Genetics
- Country
- 🇧🇯Benin
- Ownership
- -
- Employees
- -
- Market Cap
- -
- Introduction
Ocuphire Pharma, Inc. engages in the research and development of ophthalmic biopharmaceutical products. It focuses on developing and commercializing therapies for the treatment of several eye disorders. The company was founded by Mina Patel Soouch and Alan R. Meyer in February 2018 and is headquartered in Farmington Hills, MI.
Clinical Trials
46
Trial Phases
5 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (35 trials with phase data)• Click on a phase to view related trials
SENOVIE France - Therapeutic Mobility and Breast Cancer
- Conditions
- Breast Cancer Female
- First Posted Date
- 2024-07-16
- Last Posted Date
- 2024-07-16
- Lead Sponsor
- Institut de Recherche pour le Developpement
- Target Recruit Count
- 1000
- Registration Number
- NCT06503393
- Locations
- 🇫🇷
Robert Ballanger Hospital Aulnay-Sous-Bois, Aulnay-Sous-Bois, France
🇫🇷Saint-Louis University Hospital AP-HP, Paris, France
🇫🇷Delafontaine Hospital Saint-Denis, Saint-Denis, France
STREngthening COronavirus Disease 2019 (COVID-19) Surveillance in Africa
- Conditions
- COVID-19 PandemicCOVID-19SARS CoV 2 Infection
- First Posted Date
- 2023-12-14
- Last Posted Date
- 2023-12-21
- Lead Sponsor
- Institut de Recherche pour le Developpement
- Target Recruit Count
- 7000
- Registration Number
- NCT06170320
- Locations
- 🇧🇯
Institut de Recherche Clinique du Bénin, Abomey Calavi, Atlantique, Benin
The TRIple Elimination Model Of Mother-to-child Transmission Program (TRI-MOM)
- Conditions
- HBVHivSyphilis
- First Posted Date
- 2023-07-19
- Last Posted Date
- 2024-06-20
- Lead Sponsor
- Institut de Recherche pour le Developpement
- Target Recruit Count
- 2800
- Registration Number
- NCT05951751
- Locations
- 🇧🇫
Centre Muraz/INSP, Bobo-Dioulasso, Burkina Faso
🇬🇲MRC The Gambia at LSHTM, Fajara, Gambia
Efficacy and Acceptability of RUTFs in Indonesia
- Conditions
- Severe Acute Malnutrition
- First Posted Date
- 2022-11-14
- Last Posted Date
- 2022-11-14
- Lead Sponsor
- Institut de Recherche pour le Developpement
- Target Recruit Count
- 300
- Registration Number
- NCT05614505
- Locations
- 🇮🇩
Savica, Jakarta, Indonesia
TB Case-Finding, Treatment and Prevention Intervention in Thailand
- Conditions
- Tuberculosis
- First Posted Date
- 2022-10-14
- Last Posted Date
- 2024-04-24
- Lead Sponsor
- Institut de Recherche pour le Developpement
- Target Recruit Count
- 10000
- Registration Number
- NCT05581212
- Prev
- 1
- 2
- 3
- 4
- 5
- 10
- Next
News
Opus Genetics Receives FDA Clearance for BEST1 Gene Therapy Trial in Rare Inherited Retinal Disease
Opus Genetics received FDA clearance for its IND application for OPGx-BEST1, a gene therapy targeting BEST1-related inherited retinal disease.
Viatris Reports Positive Phase 3 Results for MR-142 in Treating Night Vision Disturbances After Refractive Surgery
Viatris announced positive top-line results from the Phase 3 LYNX-2 trial of MR-142, achieving its primary endpoint of ≥15-letter gain in mesopic low contrast distance visual acuity compared to placebo.
FDA Grants Fast Track Status to Opus Genetics' Eye Drop Treatment for Night Vision Impairment
Opus Genetics receives FDA Fast Track designation for Phentolamine Ophthalmic Solution 0.75% to treat night driving impairment in post-keratorefractive surgery patients.
Opus Genetics Advances LCA5 Gene Therapy Program with First Pediatric Patient Dosing and Promising Adult Data
Opus Genetics has dosed the first pediatric patient in their Phase 1/2 trial of OPGx-LCA5 gene therapy for Leber congenital amaurosis, with initial data expected by Q3 2025.
Opus Genetics Gains FDA Agreement for Phase 3 Trial of APX3330 in Diabetic Retinopathy
Opus Genetics has reached an agreement with the FDA under a Special Protocol Assessment (SPA) for a Phase 3 trial of oral APX3330.
Opus Genetics to Present 6-Month Data on OPGx-LCA5 Gene Therapy for LCA5-Associated Inherited Retinal Disease
Opus Genetics will share detailed 6-month efficacy and safety data on OPGx-LCA5, a gene therapy for LCA5-associated inherited retinal disease, at a virtual KOL event.
Ocuphire Pharma Acquires Opus Genetics, Expanding Gene Therapy Pipeline for Inherited Retinal Diseases
Ocuphire Pharma has acquired Opus Genetics in an all-stock transaction, with the combined company renamed Opus Genetics, Inc., focusing on inherited retinal diseases.